Biohaven Pharmaceutical Holding Revenue 2016-2021 | BHVN

Biohaven Pharmaceutical Holding annual/quarterly revenue history and growth rate from 2016 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Biohaven Pharmaceutical Holding revenue for the quarter ending September 30, 2021 was $0.136B, a 668.46% increase year-over-year.
  • Biohaven Pharmaceutical Holding revenue for the twelve months ending September 30, 2021 was $0.308B, a 978.84% increase year-over-year.
  • Biohaven Pharmaceutical Holding annual revenue for 2020 was $0.064B, a INF% increase from 2019.
  • Biohaven Pharmaceutical Holding annual revenue for 2019 was $0B, a NAN% decline from 2018.
  • Biohaven Pharmaceutical Holding annual revenue for 2018 was $0B, a NAN% decline from 2017.
Biohaven Pharmaceutical Holding Annual Revenue
(Millions of US $)
2020 $64
2019 $
2018 $
2017 $
2016 $
2015 $
Biohaven Pharmaceutical Holding Quarterly Revenue
(Millions of US $)
2021-09-30 $136
2021-06-30 $93
2021-03-31 $44
2020-12-31 $35
2020-09-30 $18
2020-06-30 $10
2020-03-31 $1
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $7.598B $0.064B
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00